Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Squamous Cell Carcinoma of Head and Neck 10Melanoma 8Lung Neoplasms 8Neoplasms 7Carcinoma 6Skin Neoplasms 5Neoplasm Metastasis 5Carcinoma, Squamous Cell 5Carcinoma, Basal Cell 5Adenocarcinoma 5Sarcoma 4Mouth Neoplasms 4Head and Neck Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Recurrence 3Oropharyngeal Neoplasms 3Laryngeal Neoplasms 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Hemangiosarcoma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2

Interventions

cemiplimab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Non-Small Cell Lung Carcinoma × cemiplimab × Clear all
NCT03430063 2022-11-03

A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

Regeneron Pharmaceuticals

Phase 2 Terminated
28 enrolled 16 charts
Thoracic

Advanced Non-Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡